Uncategorized
Paragon BioTeck receives affirmation of R-phenylephrine hydrochloride formulation in patent case
Paragon BioTeck announced the United States Patent and Trademark Office affirmed claims made by the company in the patent for its R-phenylephrine hydrochloride formulation, which is used to attain dilation of the pupil for ocular examinations. The ruling was handed down by the office after Altaire Pharmaceuticals sought in 2015 to invalidate Paragon’s patent that claims a method of maintaining purity of the formulation. The ruling affirmed that the petition by Altaire was without merit. This is only the fourth written decision by the Patent Trial and Appeals Board, according (Read more...)